Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer

Recruiting N/A Interventional Study
Prostate Cancer Radiotherapy Side Effect Metastatic Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Male
Study type
Interventional
Purpose
Treatment
Participants needed
420 (estimated)
Sponsor
Umeå University · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

de Novo metastatic prostate cancer with limited metastatic spread benefits from local radiotherapy to the prostate. Two different fractionation schedules will be tested.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Signed Informed Consent 2. Histological confirmed prostate cancer 3. Indication for early palliative radiation therapy of low burden metastatic prostate cancer. Low burden as defined by modified CHAARTED trial criteria to maximum 4 skeletal mets at any site and/or any number …
Contacts

Camilla Thellenberg Karlsson, MD, PhD

+46 90 785 3296

camilla.thellenberg@umu.se

CONTACT

Karin Söderkvist, MD, PhD

+4690 785 00 00

karin.soderkvist@umu.se

CONTACT